Evidence map›Paper›PMID 33047282›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2022

Mortality risk among patients undergoing exercise versus pharmacologic myocardial perfusion imaging: A propensity-based comparison.

Alan Rozanski, Heidi Gransar, Sean W Hayes, John D Friedman, Louise Thomson, Daniel S Berman

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: single photon emission computed tomography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Review
  2. Article
  3. Changing Drivers of Mortality Among Patients Referred for Cardiac Stress Testing.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Alan RozanskiThe Department of Cardiology, Mount Sinai Morningside Hospital and Mount Sinai Heart, 1111 Amsterdam Avenue, New York, 10025, USA. arozanski@chpnet.org.
Heidi GransarBurns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sean W HayesBurns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
John D FriedmanBurns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Louise ThomsonBurns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Daniel S BermanBurns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increased risk associated with pharmacologic versus exercise testing is obscured by the higher prevalence of clinical risk factors among pharmacologic patients. Thus, we assessed comparative mortality in a large risk factor-matched group of exercise versus pharmacologic patients undergoing stress/rest SPECT myocardial perfusion imaging (MPI).

methods39,179 patients undergoing stress/rest SPECT-MPI were followed for 13.3 ± 5.0 years for all-cause mortality (ACM). We applied propensity-matching to create pharmacologic and exercise groups with similar risk profiles.

resultsIn comparison to exercise patients, pharmacologic patients had an increased risk-adjusted hazard ratio for ACM for each level of ischemia: increased by 3.8-fold (95%CI 3.5-4.1) among nonischemic patients, 2.5-fold (95%CI 2.0-3.2) among mildly ischemic patients, and 2.6-fold (95%CI 2.1-3.3) among moderate/severe ischemic patients. Similar findings were observed among a propensity-matched cohort of 10,113 exercise and 10,113 pharmacologic patients as well as in an additional cohort that also excluded patients with noncardiac co-morbidities.

conclusionsPatients requiring pharmacologic stress testing manifest substantially heightened clinical risk at each level of myocardial ischemia and even when myocardial ischemia is absent. These findings suggest the need to study the pathophysiological drivers of increased risk in association with pharmacologic testing and to convey this risk in clinical reports.

Indexed as

Coronary Artery DiseaseMyocardial IschemiaMyocardial Perfusion ImagingExercise TestHumansPerfusionTomography, Emission-Computed, Single-PhotonCoronary artery diseaseMyocardial ischemiaMyocardial perfusion imagingStress testing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.